The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Australasia has a strong record in clinical trials in malignant pleural mesothelioma (MPM), driven by the relatively high incidence of this disease in the region. Two current and three proposed trials in mesothelioma in this region are discussed, covering the diverse clinical scenarios of diagnosis and staging, health-related quality of life, maintenance therapy, prediction of response and combined...
The unique growth pattern of malignant pleural mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment. Assessment of response is an important surrogate for patient benefit, particularly in phase II clinical trials. Neither the previous WHO criteria nor the more recent RECIST criteria are well suited to tumour measurement in this disease. This paper...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.